

# Intelligent Bio Solutions Partners with B2i Digital to Enhance Investor Engagement

*Collaboration focuses on raising awareness of INBS's rapid, non-invasive drug screening technology and upcoming U.S. market entry*

NEW YORK, NY, UNITED STATES, October 31, 2024 /EINPresswire.com/ -- [Intelligent Bio Solutions](#) Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company

delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with [B2i Digital](#) to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS' patented drug

“

Intelligent Bio Solutions addresses a critical need in industries requiring quick, reliable drug screening, with significant growth potential for its innovative fingerprinting technology.”

*David Shapiro, CEO, B2i Digital*

screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.

“Intelligent Bio Solutions has developed a groundbreaking system that addresses a critical need in industries requiring quick and reliable drug screening,” said David Shapiro, CEO of B2i Digital. “The company’s Intelligent Fingerprinting Drug Screening System, expected to enter the U.S. market next year following the company’s FDA 510(k) submission and anticipated clearance, provides substantial advantages over traditional methods and offers significant growth potential. We are proud to raise

awareness of a company whose products address a critical need across industries worldwide.”

B2i Digital will leverage data-driven targeting across digital channels to reach investors with a focus on healthcare technology and market innovation. The partnership will emphasize Intelligent Bio Solutions’ unique technology, growing revenue, and planned US product launch in 2025.

“As we plan for our entry into the US market, enhancing our communications and outreach to the investment community is crucial,” said Harry Simeonidis, President and CEO at Intelligent Bio




Intelligent Bio Solutions is a B2i Digital Featured Company

Solutions. "Our partnership with B2i Digital allows us to connect with investors who see the potential in our unique approach to drug screening, particularly in industries where workplace safety is paramount."

About B2i Digital, Inc.

B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, [b2idigital.com](https://b2idigital.com), and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.



B2i Digital Contact Information:

David Shapiro  
Chief Executive Officer  
B2i Digital, Inc.  
<https://b2idigital.com>  
212.579.4844 Office  
david@b2idigital.com

<https://www.linkedin.com/in/davidshapironyc>  
<https://www.linkedin.com/company/b2i-digital>

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a

valuable tool for employers in safety-critical industries. The company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: <http://www.ibs.inc/>

Intelligent Bio Solutions Company Contact: ☐☐

Intelligent Bio Solutions Inc. ☐

info@ibs.inc ☐

<https://www.linkedin.com/company/ibsinc/> ☐

[https://x.com/ibs\\_inc](https://x.com/ibs_inc)

Intelligent Bio Solutions Investor & Media Contact: ☐

Valter Pinto, Managing Director ☐

KCSA Strategic Communications ☐

PH: (212) 896-1254 ☐

INBS@kcsa.com

David Shapiro

B2i Digital, Inc.

+1 917-806-4171

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[TikTok](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/756422572>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.